MN1 overexpression with varying tumor grade is a promising predictor of survival of glioma patients.
Journal
Human molecular genetics
ISSN: 1460-2083
Titre abrégé: Hum Mol Genet
Pays: England
ID NLM: 9208958
Informations de publication
Date de publication:
06 01 2021
06 01 2021
Historique:
received:
25
07
2020
revised:
10
10
2020
accepted:
12
10
2020
pubmed:
27
10
2020
medline:
29
9
2021
entrez:
26
10
2020
Statut:
ppublish
Résumé
Gliomas have substantial mortality to incidence rate ratio and a dismal clinical course. Newer molecular insights, therefore, are imperative to refine glioma diagnosis, prognosis and therapy. Meningioma 1 (MN1) gene is a transcriptional co-regulator implicated in other malignancies, albeit its significance in glioma pathology remains to be explored. IGFBP5 is regulated transcriptionally by MN1 and IGF1 and is associated with higher glioma grade and shorter survival time, prompting us to ascertain their correlation in these tumors. We quantified the expression of MN1, IGFBP5 and IGF1 in 40 glioma samples and examined their interrelatedness. MN1 mRNA-protein inter-correlation and the gene's copy number were evaluated in these tumors. Publicly available TCGA datasets were used to examine the association of MN1 expression levels with patient survival and for validating our findings. We observed MN1 overexpression correlated with low-grade (LGGs) and not high-grade gliomas and is not determined by the copy number alteration of the gene. Notably, gliomas with upregulated MN1 have better overall survival (OS) and progression-free survival (PFS). IGFBP5 expression associated inversely with MN1 expression levels in gliomas but correlated positively with IGF1 expression in only LGGs. This suggests a potential grade-specific interplay between repressive and activating roles of MN1 and IGF1, respectively, in the regulation of IGFBP5. Thus, MN1 overexpression, a promising predictor of OS and PFS in gliomas, may serve as a prognostic biomarker in clinical practice to categorize patients with survival advantage.
Identifiants
pubmed: 33105486
pii: 5940464
doi: 10.1093/hmg/ddaa231
pmc: PMC7788295
doi:
Substances chimiques
Biomarkers, Tumor
0
MN1 protein, human
0
Trans-Activators
0
Tumor Suppressor Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3532-3545Subventions
Organisme : DBT-Wellcome Trust India Alliance
ID : IA/E/16/1/503028
Pays : India
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
Références
Cancer Genet Cytogenet. 1993 Mar;66(1):1-10
pubmed: 8467468
Neuroscience. 2007 Mar 30;145(3):795-811
pubmed: 17320297
Cancer Res. 1988 Mar 1;48(5):1233-7
pubmed: 2963688
J Biol Chem. 1996 Feb 23;271(8):4280-8
pubmed: 8626775
J Mol Endocrinol. 2007 Feb;38(1-2):113-25
pubmed: 17242174
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Am J Hum Genet. 1991 Apr;48(4):783-90
pubmed: 2014801
Oncogene. 1995 Apr 20;10(8):1521-8
pubmed: 7731706
Endocr Rev. 2007 Feb;28(1):20-47
pubmed: 16931767
Neurosurgery. 1989 Jun;24(6):791-7
pubmed: 2546092
Breast Cancer Res. 2008;10(4):212
pubmed: 18710598
Carcinogenesis. 2008 Oct;29(10):2025-34
pubmed: 18632758
Proteomics. 2006 May;6(10):2964-71
pubmed: 16619307
Oncotarget. 2016 Nov 8;7(45):74031-74042
pubmed: 27677590
Cancer Lett. 2003 Jun 10;195(2):127-37
pubmed: 12767520
Neurosci Lett. 1988 Oct 31;93(1):114-9
pubmed: 3211366
Exp Cell Res. 2005 Apr 15;305(1):179-89
pubmed: 15777798
Cell Div. 2020 Feb 27;15:4
pubmed: 32127912
Arch Pathol Lab Med. 2011 May;135(5):558-68
pubmed: 21526954
Acta Neuropathol. 2018 Mar;135(3):481-484
pubmed: 29372318
Front Oncol. 2017 Sep 29;7:236
pubmed: 29034211
J Endocrinol. 2002 Mar;172(3):423-40
pubmed: 11874691
Acta Neuropathol. 2007 Aug;114(2):97-109
pubmed: 17618441
Gene. 2012 Apr 15;497(2):155-63
pubmed: 22330882
Cancer Res. 1993 Jun 1;53(11):2475-8
pubmed: 8495408
J Clin Endocrinol Metab. 1993 Nov;77(5):1246-50
pubmed: 7521344
Endocrinology. 1998 Jan;139(1):65-71
pubmed: 9421399
Nucleic Acids Res. 2013 Jan;41(Database issue):D991-5
pubmed: 23193258
Genes Dev. 2007 Nov 1;21(21):2683-710
pubmed: 17974913
Neuro Oncol. 2018 Oct 1;20(suppl_4):iv1-iv86
pubmed: 30445539
Oncotarget. 2015 Aug 21;6(24):20636-49
pubmed: 26010068
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Cancer Epidemiol Biomarkers Prev. 2010 Jun;19(6):1399-408
pubmed: 20501753
Science. 1987 Apr 10;236(4798):193-7
pubmed: 3563497
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
Mol Oncol. 2013 Jun;7(3):704-18
pubmed: 23562353
Arch Pathol Lab Med. 2018 Jul;142(7):804-814
pubmed: 29775073
J Biol Chem. 1993 Oct 25;268(30):22305-12
pubmed: 7693664
Neuro Oncol. 2014 Jul;16(7):896-913
pubmed: 24842956
Technol Cancer Res Treat. 2006 Jun;5(3):195-9
pubmed: 16700616
Nat Rev Cancer. 2014 May;14(5):329-41
pubmed: 24722429
Nat Rev Neurol. 2019 Jul;15(7):405-417
pubmed: 31227792
Endocr Rev. 2005 Dec;26(7):916-43
pubmed: 16131630
Acta Neuropathol. 2018 Nov;136(5):805-810
pubmed: 30259105
J Neurosci. 1993 Dec;13(12):5092-104
pubmed: 7504720
J Neurosurg. 2011 Nov;115(5):948-65
pubmed: 22043865
Acta Neuropathol. 2018 Apr;135(4):639-642
pubmed: 29497819
Biochim Biophys Acta. 1996 Nov 8;1314(1-2):83-92
pubmed: 8972721
Nature. 2017 Sep 28;549(7673):533-537
pubmed: 28959975
Endocrinology. 2005 Jul;146(7):3096-104
pubmed: 15845624
J Clin Endocrinol Metab. 1990 Jul;71(1):199-209
pubmed: 2164527
Neuro Oncol. 1999 Apr;1(2):109-19
pubmed: 11550306
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
Acta Neuropathol. 2019 Apr;137(4):683-687
pubmed: 30848347
Brain. 2019 Jan 1;143(1):55-68
pubmed: 31834374
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Horm Metab Res. 1988 Jul;20(7):436-42
pubmed: 2971601
Neurosurg Focus. 2015 Jan;38(1):E6
pubmed: 25552286